{"id":"dapagliflozin-dapa","brandName":"Dapagliflozin (DAPA)","genericName":"Dapagliflozin (DAPA)","companyId":"ottawa-heart-institute-research-corporation","companyName":"Ottawa Heart Institute Research Corporation","phase":"marketed","status":"active","modality":"Small molecule","aliases":["Dapagliflozin","• Farxiga","• SGLT2 inhibitor","iSGLT2","SGLT2 inhibitor"],"developmentCodes":[],"firstApprovalDate":null,"firstApprovalCountry":null,"aiSummary":"Dapagliflozin, developed by the Ottawa Heart Institute Research Corporation, is an SGLT2 inhibitor used primarily for the treatment of type 2 diabetes mellitus. It works by inhibiting the reabsorption of glucose in the kidneys, leading to increased urinary glucose excretion and reduced blood glucose levels. Despite its efficacy, dapagliflozin does not have an FDA label, which may limit its use in certain markets. Common side effects include urinary tract infections and genital fungal infections, occurring in about 3-5% of patients. The drug is also under investigation for potential cardiovascular benefits.","enrichmentLevel":3,"visitCount":0,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By blocking SGLT2, dapagliflozin prevents the reabsorption of filtered glucose in the proximal tubule of the nephron, leading to increased urinary glucose loss and lower blood glucose levels. Beyond glycemic control, SGLT2 inhibition has cardioprotective and renoprotective effects, reducing heart failure hospitalizations and slowing diabetic kidney disease progression.","oneSentence":"Dapagliflozin inhibits sodium-glucose cotransporter 2 (SGLT2) in the kidney, reducing glucose reabsorption and increasing urinary glucose excretion.","_ai_confidence":"high"},"administration":{},"safety":{"commonSideEffects":[{"rate":"10–15","effect":"Genital mycotic infections"},{"rate":"5–10","effect":"Urinary tract infections"},{"rate":"5–10","effect":"Polyuria"},{"rate":"5–10","effect":"Hypotension"},{"rate":"0.1–0.5","effect":"Diabetic ketoacidosis"}]},"trials":[],"indications":{"approved":[{"name":"Type 2 diabetes mellitus"},{"name":"Heart failure with reduced ejection fraction"},{"name":"Chronic kidney disease"}]},"commercial":null,"patents":[],"timeline":[],"rwe":[],"competitors":[],"ownershipHistory":[],"trialDetails":[],"genericFilers":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"labelChanges":[],"nice":null,"revenue":null,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":false,"score":3}}